Teva Settles Litigation With Novartis Over Generic Lotrel
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. settled patent litigation related to its generic versions of Novartis AG’s Lotrel blood-pressure drug.
Financial terms of the settlement are confidential, Petach Tikva, Israel-based Teva said today in a regulatory filing. U.S. District Judge Garrett E. Brown Jr. in Newark, New Jersey, approved the dismissal of the litigation in an order signed yesterday, according to a court filing.